The prevalence of diabetes in Oklahoma is higher than in most other states and thus, diabetes constitutes a major threat to the working-age and older population and confers an immense social and economic burden on Oklahoma. The goal of this COBRE is to enhance diabetes research in Oklahoma. In the past four years of the COBRE project, three junior investigators supported by the COBRE have successfully obtained NIH R01 grants as PI, and two others have obtained independent grants from the American Diabetes Association and the American Heart Association. Two of our junior investigators have been recently promoted to Associate Professor. Between them, the COBRE-funded junior investigators have published 104 papers. All of the junior investigators who graduated from the COBRE remain in Oklahoma and will continue to participate actively in our COBRE. In collaboration with the Department of Geriatric Medicine, the COBRE has recently recruited another junior diabetes researcher to Oklahoma. The COBRE has also established four core facilities, which have provided support and service to our diabetes research community. These successes have greatly contributed to the growth and productivity of diabetes research in Oklahoma. In Phase II of our COBRE program, we plan to sustain and augment these successes, with the following objectives: 1) To continue mentoring promising junior investigators (PJI) and early career investigators (ECI) in diabetes research in Oklahoma by providing funding, mentoring and essential core facilities. 2) To continue to recruit diabetes researchers to Oklahoma. The COBRE plans to recruit at least three new diabetes researchers to Oklahoma in next five years in collaboration with the University and the Harold Hamm Diabetes Center. 3) To consolidate and improve our core facilities to serve diabetes research in Oklahoma. We will prepare the transition of the COBRE-funded Cores to institution-supported facilities after the completion of the COBRE funding. 4) To foster and promote collaboration among diabetes researchers across the state. 5) To enhance collaboration between clinicians and basic scientists and to promote translational research. The COBRE will provide training in translational research and access to diabetic patient sample for PJI and ECl.

Public Health Relevance

Diabetes is developing into a pandemic of the 21st century. Its prevalence in Oklahoma is higher than in most other states, with 10% of the population affected. Diabetes represents a major threat to the health of the working population, and constitutes an immense social and economic burden in Oklahoma. This program is to train and recruit more diabetes researchers in Oklahoma and enhance diabetes research.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM104934-07
Application #
8542659
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Program Officer
Douthard, Regine
Project Start
2007-09-15
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
7
Fiscal Year
2013
Total Cost
$2,109,366
Indirect Cost
$596,196
Name
University of Oklahoma Health Sciences Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Orock, Albert; Logan, Sreemathi; Deak, Ferenc (2018) Munc18-1 haploinsufficiency impairs learning and memory by reduced synaptic vesicular release in a model of Ohtahara syndrome. Mol Cell Neurosci 88:33-42
Wang, Bing; Li, Pui-Kai; Ma, Jian-Xing et al. (2018) Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. Invest Ophthalmol Vis Sci 59:3630-3642
Shin, Younghwa; Moiseyev, Gennadiy; Petrukhin, Konstantin et al. (2018) A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis 1864:2420-2429
Fu, Shuhua; Dong, Shuqian; Zhu, Meili et al. (2018) VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases. Adv Exp Med Biol 1074:473-478
Chen, Qian; Qiu, Fangfang; Zhou, Kelu et al. (2017) Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPAR?. Diabetes 66:1671-1682
Du, Mei; Martin, Ashley; Hays, Franklin et al. (2017) Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4. Mol Vis 23:185-197
Malechka, Volha V; Moiseyev, Gennadiy; Takahashi, Yusuke et al. (2017) Impaired Rhodopsin Generation in the Rat Model of Diabetic Retinopathy. Am J Pathol 187:2222-2231
Qiu, Fangfang; Liu, Zhen; Zhou, Yueping et al. (2017) Decreased Circulating Levels of Dickkopf-1 in Patients with Exudative Age-related Macular Degeneration. Sci Rep 7:1263
Pearsall, Elizabeth A; Cheng, Rui; Zhou, Kelu et al. (2017) PPAR? is essential for retinal lipid metabolism and neuronal survival. BMC Biol 15:113
Le, Yun-Zheng (2017) VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases. Vision Res 139:108-114

Showing the most recent 10 out of 101 publications